Free
Meeting Abstracts  |   December 1997
Interaction between Anesthetics and the Sodium-Hydrogen Exchange Inhibitor HOE 642 (Cariporide) in Ischemic and Reperfused Rat Hearts 
Author Notes
  • (Mathur) Anesthesia Resident.
  • (Karmazyn) Professor and Career Investigator of the Heart and Stroke Foundation of Ontario.
  • Received from the Departments of Pharmacology and Toxicology and Anaesthesia, University of Western Ontario, London, Ontario, Canada. Submitted for publication April 4, 1997. Accepted for publication August 6, 1997. Supported by the Medical Research Council of Canada and the Department of Anaesthesia, University of Western Ontario. No funding from industrial sources was obtained for this study. Presented by Dr. Mathur at the Annual Meeting of the Midwest Anesthesiology Residents Conference, Chicago, Illinois, April 4–6, 1997. Dr. Mathur received the first prize award for basic science poster presentations.
  • Address reprint requests to Dr. Karmazyn: Department of Pharmacology and Toxicology, University of Western Ontario, Medical Sciences Building, London, Ontario, Canada N6A 5C1. Address electronic mail to: mkarm@julian.uwo.ca.
Article Information
Meeting Abstracts   |   December 1997
Interaction between Anesthetics and the Sodium-Hydrogen Exchange Inhibitor HOE 642 (Cariporide) in Ischemic and Reperfused Rat Hearts 
Anesthesiology 12 1997, Vol.87, 1460-1469. doi:
Anesthesiology 12 1997, Vol.87, 1460-1469. doi:
Sodium (Na sup +)-Hydrogen (H sup +) exchange (NHE) represents an important mechanism for proton extrusion after ischemia-induced acidosis, which acts by extruding protons in exchange for sodium entry in a 1:1 stoichiometric relation. [1,2 ] Paradoxically, however, NHE activation also contributes to myocardial ischemic and reperfusion injury, and inhibition of the antiporter has been extensively demonstrated to protect the ischemic and reperfused myocardium against injury (reviewed in [3–6 ]). The involvement of NHE in cardiac injury likely reflects the fact that the sodium, which enters in exchange for proton efflux, cannot be effectively removed because of reduced Na sup +-K sup + adenosine triphosphatase (ATPase) activity. The intracellular Na sup + accumulation then results in elevations in intracellular Ca2+ concentrations due to decreased elimination or possibly increased entry of Ca2+ via the Na sup +-Ca2+ exchange. [4–6 ] This ionic imbalance and intracellular calcium overload contributes to cell injury, [6 ] contracture, and depressed systolic function. [5 ] Sodium and hydrogen exchange inhibitors have been proposed as superior cardioprotective agents that could be effective as adjuncts to cardioplegic solutions during cardiac surgery. [7 ] Indeed, the potent and cardiac NHE isoform-specific (NHE-1) inhibitor HOE 642 (cariporide) is currently being evaluated in clinical trial as a cardioprotective agent in high-risk patients with acute coronary syndrome, including those having coronary artery bypass surgery. However, interaction between NHE inhibitors and anesthetic agents has not been studied yet. This is particularly important because volatile anesthetics, including sevoflurane and isoflurane, have cardiac effects and indeed have been shown to exert a protective influence on the ischemic myocardium. [8–20 ] Although there is evidence for cardioprotective effects of various volatile anesthetics, to our knowledge the influence of sufentanil has not been previously studied, although morphine and activation of opioid receptors have been shown to be involved in mediating the protective effects of myocardial preconditioning. [21 ] However, the precise role of opioid receptor activation in myocardial injury has not been elucidated because naloxone, an opioid receptor blocker, has also been shown to protect the ischemic and reperfused myocardium. [22 ] Accordingly, the present study was done to determine the effect of HOE 642 on the ischemic and reperfused heart in the presence of either isoflurane or sevoflurane as well as sufentanil and to assess potential interactions between HOE 642 and these agents on the ischemic and reperfused heart.
Materials and Methods 
Animals 
Male Sprague-Dawley rats (weighing 250–300 g) were purchased from Charles-River Canada (St. Constant, Quebec, Canada) or Harland Sprague-Dawley (Indianapolis, IN). The animals were maintained in the Health Sciences Animal Care Facility of the University of Western Ontario in accordance with the guidelines of the Canadian Council on Animal Care (Ottawa, Ontario, Canada)
Heart Perfusion 
Rats were killed by decapitation and the hearts were immediately excised and placed in cold Krebs-Henseleit buffer to stop contractions. The hearts were picked up by the aorta and prepared for retrograde perfusion using a modified Langendorff method at a constant flow rate of 10 ml/min using a peristaltic pump. The perfusion fluid (pH, 7.4; temperature, 37 [degree sign] Celsius) was Krebs-Henseleit buffer containing 120 mM NaCl, 4.63 mM KCl, 1.17 mM KH2PO4, 1.25 mM CaCl2, 1.2 mM MgCl2, 20 mM NaHCO3, and 8 mM glucose. The buffer was vigorously gassed with 95% oxygen and 5% carbon dioxide before addition of drugs. Coronary pressure was measured via a side arm of the perfusion cannula connected to a pressure transducer (Spectramed P23XL, Oxnard, CA). A latex water-filled balloon fixed to a pressure transducer was inserted through the mitral valve into the left ventricle to determine left ventricular developed pressure. Positive and negative dP/dt (rates of pressure development or relaxation) were calculated using a differentiator. Left ventricular end-diastolic pressure was adjusted to approximately 5 mmHg before starting the experiment by adjusting the volume in the intraventricular balloon with the aid of a micrometer-equipped syringe. Hearts were electrically paced at three times the voltage threshold with a stimulator set at 5 Hz. Pacing was also maintained during the ischemic period. All determinations of ventricular and coronary pressures were obtained on-line on a Pentium 586 computer using a Biopac data analysis system (Biolynx Scientific Equipment, Montreal, Quebec, Canada).
Experimental Protocol 
Hearts were initially equilibrated for 20 min, after which either isoflurane, sevoflurane (delivery and concentrations described subsequently), sufentanil (1.21 nM, calculated to be equivalent to 1.6 micro gram [center dot] kg body weight sup -1 [center dot] h sup -1) was added for an additional 15 min either alone or simultaneously with HOE 642 (5 micro Meter). Other experiments were done in which HOE 642 alone was administered in the absence of anesthetic. Control hearts were perfused with drug-free buffer for an equal period of time.
At the end of the 15-min drug-treatment period, hearts were rendered globally ischemic by completely shutting off the flow for 60 min, after which reperfusion at a normal flow rate was initiated for a further 60 min. The respective drug treatment was maintained throughout the reperfusion period.
Anesthetic Delivery and Determination of Concentrations 
Volatile anesthetics were injected directly into sealed 4–1 glass bottles each containing 1 l preoxygenated perfusate (pH, 7.39 +/- 0.02; carbon dioxide pressure, 30 +/- 5 mmHg; and oxygen pressure, 818 +/- 31 mmHg) as described by Boban et al. [23 ] A gas-tight syringe equipped with a gas-tight stainless steel valve (Hamilton 1000 series syringe, Hamilton GTS valve H86560 VWR Canlab, Mississauga, Ontario, Canada) was used to aspirate and inject the volatile anesthetics. Specific volumes of sevoflurane and isoflurane were injected immediately into the designated sealed glass bottle using a double stopcock system to avoid leakage and volatilization of the anesthetics before and during injection. The sealed perfusate was stirred continuously to facilitate equilibration of the volatile anesthetics between the liquid and gas phases.
To ensure that anesthetic concentrations were maintained throughout the entire perfusion period, samples of perfusate were collected at the aortic outlet just before ischemia and 60 min after reperfusion to determine anesthetic concentrations by gas chromatography using a Varian (Mississauga, Ontario, Canada) 3300 gas chromatograph equipped with a J & W Scientific (VWR Canlab) DB-1 high-resolution gas chromatography column. The anesthetic concentrations before ischemia were 0.308 +/- 0.020 mM for isoflurane and 0.307 +/- 0.03 mM for sevoflurane, whereas the respective values after 60 min reperfusion were 0.30 +/- 0.02 mM and 0.301 +/- 0.040 mM. Effective volume percentage concentrations were calculated as 1.42 vol% for isoflurane (0.93 minimum alveolar concentration [MAC]) and 2.17 vol% for sevoflurane (1.03 MAC) before ischemia and 1.39 vol%(0.92 MAC) and 2.13 vol%(1.01 MAC) at the end of reperfusion, respectively, using Krebs-Ringer's solution/gas partition coefficients of 0.55 for isoflurane and 0.36 for sevoflurane at 37 [degree sign] Celsius and 1 atm, as described previously. [24 ]
Metabolite Assays 
At the end of the reperfusion period, hearts were clamped with Wollenberger tongs precooled in liquid nitrogen, removed from the cannula, and stored in liquid nitrogen until enzymatic determination for energy metabolites, as previously described. [25 ]
Data Analysis 
All values are given as mean +/- SEM. Multifactorial analysis of variance and Tukey's test for multiple comparisons were used to determine the effects of anesthetics and HOE 642 on ischemic contracture, metabolite content, and hemodynamic function at each time interval during postischemic reperfusion. Differences among the experimental groups were assessed by one-way analysis of variance. Differences were considered significant at P < 0.05.
Results 
Basal Hemodynamic Function 
As summarized in Table 1, there were no significant differences among the groups with respect to baseline hemodynamic function in terms of left ventricular developed pressure after the initial 20-min equilibration perfusion period (BL1). Furthermore, no effects were observed with subsequent 15-min exposure to either sufentanil, sevoflurane, or HOE 642 with respect to any parameter (BL2). Isoflurane produced a modest negative inotropic effect with a maximum contractile depression of 15.7%, but preischemic values for all parameters in the presence of isoflurane were not significantly different from any of the other treatment groups. In addition, left ventricular end-diastolic pressure, which was initially adjusted to 5 mmHg, was completely unaffected by any of the drugs or drug combinations (data not shown).
Table 1. Baseline Values of LV Developed Pressure 
Image not available
Table 1. Baseline Values of LV Developed Pressure 
×
Functional Response to Ischemia and Reperfusion 
(Figure 1) summarizes the effect of sevoflurane and HOE 642 on recovery of left ventricular developed pressure and elevation in left ventricular end-diastolic pressure during reperfusion. These results show that sevoflurane significantly improved recovery of left ventricular developed pressure from control hearts after 15 min of reperfusion. Although HOE 642 improved the magnitude of recovery to a level not significantly different from sevoflurane, recovery in the presence of the NHE inhibitor occurred more rapidly and to a greater degree during early reperfusion when compared with either control hearts or hearts treated with sevoflurane only (Figure 1). Thus recovery was significantly higher (P < 0.05) as early as 5 min after initiating reperfusion, which continued throughout reperfusion when compared with control, and for the first 15 min compared with recovery obtained with sevoflurane alone (Figure 1). A combination of sevoflurane plus HOE 642 exerted significantly superior recovery of left ventricular developed pressure compared with all other groups; indeed, functional recovery after 5 min of reperfusion reached 100% of preischemia values (Figure 1). Surprisingly, continued reperfusion in the presence of both sevoflurane and HOE 642 produced a greater than 100% recovery in left ventricular developed pressure (Figure 1).
Figure 1. Effects of sevoflurane (SEVO) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for SEVO + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with control at all times during reperfusion and compared with sevoflurane alone for the first 15 min. The sevoflurane-alone group was significantly higher than controls from 15 min until the end of reperfusion.
Figure 1. Effects of sevoflurane (SEVO) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for SEVO + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with control at all times during reperfusion and compared with sevoflurane alone for the first 15 min. The sevoflurane-alone group was significantly higher than controls from 15 min until the end of reperfusion.
Figure 1. Effects of sevoflurane (SEVO) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for SEVO + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with control at all times during reperfusion and compared with sevoflurane alone for the first 15 min. The sevoflurane-alone group was significantly higher than controls from 15 min until the end of reperfusion.
×
(Figure 1) also demonstrates left ventricular end-diastolic pressure changes during reperfusion and shows that sevoflurane alone failed to depress contracture development. HOE 642 significantly reduced the elevation in left ventricular end-diastolic pressure either by itself or in the presence of sevoflurane. However, with respect to the latter drug combination, left ventricular end-diastolic pressure was significantly lower than values obtained with HOE 642 alone during the initial 25 min of reperfusion (Figure 1). Figure 2shows an example of individual responses in a control heart and in a heart treated with HOE 642 and sevoflurane.
Figure 2. Examples of developed pressure recordings from a control heart (A) or a heart to which HOE 642 and sevoflurane were added (B). Ischemia (I) and reperfusion (R) were each initiated for 60 min. The horizontal marker bar indicates 20 min, whereas the vertical bar indicates 20 mmHg developed pressure. Note the reduced increase in end-diastolic pressure with the drug combination and the more rapid and pronounced recovery of developed pressure, which reached a maximum value of 127% of preischemia values.
Figure 2. Examples of developed pressure recordings from a control heart (A) or a heart to which HOE 642 and sevoflurane were added (B). Ischemia (I) and reperfusion (R) were each initiated for 60 min. The horizontal marker bar indicates 20 min, whereas the vertical bar indicates 20 mmHg developed pressure. Note the reduced increase in end-diastolic pressure with the drug combination and the more rapid and pronounced recovery of developed pressure, which reached a maximum value of 127% of preischemia values.
Figure 2. Examples of developed pressure recordings from a control heart (A) or a heart to which HOE 642 and sevoflurane were added (B). Ischemia (I) and reperfusion (R) were each initiated for 60 min. The horizontal marker bar indicates 20 min, whereas the vertical bar indicates 20 mmHg developed pressure. Note the reduced increase in end-diastolic pressure with the drug combination and the more rapid and pronounced recovery of developed pressure, which reached a maximum value of 127% of preischemia values.
×
As is shown in Figure 3, a virtually identical profile was evident with isoflurane with respect to recovery of developed pressure (Figure 3) and elevation of left ventricular end-diastolic pressure during reperfusion (Figure 3), similar to that observed with sevoflurane. Thus isoflurane significantly improved functional recovery in the absence of any salutary effect on left ventricular end-diastolic pressure. HOE 642 combined with isoflurane produced a greater than 100% recovery in function after reperfusion and significantly attenuated the elevation in left ventricular end-diastolic pressure.
Figure 3. Effects of isoflurane (ISOF) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for the ISOF + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with controls at all times during reperfusion and compared with isoflurane alone for the first 25 min. The isoflurane-alone group was significantly higher than controls from 25 min until the end of reperfusion.
Figure 3. Effects of isoflurane (ISOF) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for the ISOF + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with controls at all times during reperfusion and compared with isoflurane alone for the first 25 min. The isoflurane-alone group was significantly higher than controls from 25 min until the end of reperfusion.
Figure 3. Effects of isoflurane (ISOF) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for the ISOF + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with controls at all times during reperfusion and compared with isoflurane alone for the first 25 min. The isoflurane-alone group was significantly higher than controls from 25 min until the end of reperfusion.
×
Sufentanil had no direct cardioprotective effects with respect to developed pressure (Figure 4, top panel) and, when present on its own, produced a sustained elevation in left ventricular end-diastolic pressure during re-perfusion (Figure 4, bottom panel). However, the protective influence of HOE 642 was maintained, although with this opioid identical effects of HOE 642 were evident regardless of the presence of sufentanil. Furthermore, HOE 642 prevented the elevation in end-diastolic pressure seen with sufentanil alone (Figure 4, bottom panel).
Figure 4. Effects of sufentanil (SUFN) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for either the HOE-alone or HOE + SUFN groups compared with the two other treatments. #P < 0.05 from control. n = 6 for all groups except control (n = 7).
Figure 4. Effects of sufentanil (SUFN) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for either the HOE-alone or HOE + SUFN groups compared with the two other treatments. #P < 0.05 from control. n = 6 for all groups except control (n = 7).
Figure 4. Effects of sufentanil (SUFN) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for either the HOE-alone or HOE + SUFN groups compared with the two other treatments. #P < 0.05 from control. n = 6 for all groups except control (n = 7).
×
As summarized in Table 2, recovery of +/- dP/dt paralleled the responses observed with respect to left ventricular developed pressure in all treatment groups.
Table 2. Rates of LV Pressure Development (+dP/dt) and LV Relaxation (-dP/dt) as a Percentage of Baseline during Reperfusion (5, 30, and 60 min) 
Image not available
Table 2. Rates of LV Pressure Development (+dP/dt) and LV Relaxation (-dP/dt) as a Percentage of Baseline during Reperfusion (5, 30, and 60 min) 
×
There were no significant differences in coronary perfusion pressure among any of the treatment groups (data not shown).
We also studied these treatments to determine if they affect contracture development during the ischemic period in terms of the maximum elevation of left ventricular end-diastolic pressure and the duration required to reach this value. Figure 5summarizes these results. As shown in this figure, maximum left ventricular end-diastolic pressure reached during ischemia was significantly reduced by HOE 642 but not by any of the anesthetic agents. Furthermore, the time required to reach peak elevation in left ventricular end-diastolic pressure was significantly prolonged only by HOE 642. The beneficial effects of HOE 642 were also seen when the drug was present in combination with any of the anesthetic agents (Figure 5).
Figure 5. Changes in maximum left ventricular end-diastolic pressure (LVEDP) and the time to peak LVEDP during 60 min of ischemia. Values are mean +/- SEM. C = control; S = sevoflurane (Sevo); I = isoflurane (Isof); SF = sufentanil (Sufn); H = HOE 642. *P < 0.05 compared with unlabeled groups.
Figure 5. Changes in maximum left ventricular end-diastolic pressure (LVEDP) and the time to peak LVEDP during 60 min of ischemia. Values are mean +/- SEM. C = control; S = sevoflurane (Sevo); I = isoflurane (Isof); SF = sufentanil (Sufn); H = HOE 642. *P < 0.05 compared with unlabeled groups.
Figure 5. Changes in maximum left ventricular end-diastolic pressure (LVEDP) and the time to peak LVEDP during 60 min of ischemia. Values are mean +/- SEM. C = control; S = sevoflurane (Sevo); I = isoflurane (Isof); SF = sufentanil (Sufn); H = HOE 642. *P < 0.05 compared with unlabeled groups.
×
Energy Metabolite Contents 
(Table 3) provides a summary of energy metabolite content in reperfused hearts subjected to various treatments. Significant preservation of adenosine triphosphate (ATP) stores and energy charge was seen in all hearts treated with HOE 642 either by itself or in the presence of volatile anesthetics. Surprisingly, no significant effects on ATP stores or energy charge were evident with HOE 642 in combination with sufentanil. None of the anesthetics by themselves had any affect on these parameters.
Table 3. Energy Metabolite Concentrations 
Image not available
Table 3. Energy Metabolite Concentrations 
×
Discussion 
Our study was done to determine the potential interactions between the NHE inhibitor HOE 642 and general anesthetics, which could have clinical relevance and also further our understanding of the mechanisms underlying the protective effects of these agents. Although NHE represents a major mechanism for recovery of intracellular acidosis in the ischemic myocardium, it also contributes to ischemic and reperfusion injury in the heart through a mechanism that likely involves a secondary elevation in intracellular Ca2+ levels. [3–6 ] Briefly, this concept reflects the fact that the Na sup +-K sup + ATPase is inhibited, resulting in inefficient removal of Na sup + and elevation of intracellular Na sup + concentrations, followed by elevations in intracellular Ca2+ concentrations due either to its reduced removal through the Na sup +-Ca2+ exchanger or reverse-mode Na sup +-Ca2+ exchange activity resulting in active Ca2+ entry. A role for NHE involvement in cardiac ischemic and reperfusion injury is supported by many studies that have universally demonstrated excellent cardioprotection using various experimental models and animal species and NHE inhibitors (reviewed in [3–6 ]). Therefore we have proposed that NHE inhibition represents an effective and safe approach to cardiac protection and preservation, including as a cardioplegic adjunct in cardiac surgery. [7 ] HOE 642 is of particular interest because it is highly selective in inhibiting NHE in the myocardium without affecting other membrane ion transport systems, and it exerts marked cardioprotective effects. [26 ] Furthermore, this agent is being evaluated clinically in a multicenter international study in high-risk patients with acute coronary syndrome, including persons having coronary artery bypass graft surgery. Accordingly, we wanted to determine whether this agent still exerts cardioprotection in the presence of general anesthetics used in cardiac surgery, including volatile anesthetics and the opioid sufentanil.
We must state that volatile anesthetics also produce complex effects, including modulation of intracellular calcium homeostasis. [27–31 ] Furthermore, volatile anesthetics inhibit both Ca2+ channels and the Na sup +-Ca2+ exchange at concentrations relevant to clinical anesthesia. [24 ] Wilde et al. [28 ] found that at clinically relevant concentrations, volatile anesthetics reduce the Ca2+ influx during membrane excitation and reduce the SR release of Ca2+. One report indicated that these agents may decrease the calcium sensitivity in myocardial cells, although this study was limited to hypothermic conditions. [29 ] Volatile anesthetics also improve postischemic ventricular recovery, [8–20 ] which was also obviously evident in our study, which showed increased ventricular functional recovery; in contrast to HOE 642, however, no significant attenuation of contracture development (increase in left ventricular end-diastolic pressure) during ischemia or reperfusion was evident. Furthermore, with respect to comparisons between the two drug groups, it is interesting that although the magnitude of ventricular recovery was identical, HOE 642-treated hearts recovered significantly faster after restoration of flow. This difference is consistent with distinct and separate mechanisms of action for cardioprotection by volatile anesthetics. In this regard, it has been proposed that activation of ATP-sensitive potassium channels (KATP) likely represents the mechanism for the salutary actions of isoflurane because glyburide, a KATPblocker, prevents the protection afforded by this agent. [19,20 ] However, using isolated rabbit cardiomyocytes, investigators have reported that isoflurane inhibits KATP. [32 ] These authors also showed, on the other hand, that isoflurane decreases channel sensitivity to ATP which, in effect, would support the involvement of KATPin the cardioprotective effect of this anesthetic. Although the mechanism for KATPinvolvement is not known with certainty, one proposed explanation suggests that this would result in decreased action potential duration and decreased Ca2+ entry, although this concept is not universally accepted (reviewed by Grover [33 ]). Because volatile anesthetics and NHE inhibitors may act by decreasing intracellular Ca2+ levels, the dissimilar protective profile shown in our study argues against decreased Ca2+ entry and energy use associated with action potential shortening as the sole mechanism. Alternatively, it is possible that the inability of volatile anesthetics to inhibit contracture may reflect additional effects of these drugs, which counter the protective influence such as inhibition of Na sup +-Ca2+ exchange, [24 ] which is a route of Ca2+ removal from the cardiac cell during diastole. Therefore, inhibition of Na sup +-Ca2+ exchange by volatile anesthetics may actually increase intracellular Ca2+ levels during ischemia and reperfusion, resulting in decreased cardioprotection.
An interesting and surprising finding of our study was the excellent recovery of function observed in hearts treated with the combination of volatile anesthetic and HOE 642, which often exceeded preischemic function. Although this likely represented additive effects due to distinct mechanisms of protection by these agents, the basis for more than 100% recovery observed in some hearts, as illustrated in Figure 2, can only be a matter of speculation. The phenomenon may possibly reflect myofibrillar sensitization to Ca2+ in the reperfused heart due to the drug combination, although this concept needs to be addressed with further studies. It should also be emphasized that the superior functional recovery when hearts were treated with a combination of HOE 642 and the volatile anesthetic was particularly evident during the first 30 min of reperfusion, with contractility declining modestly with continued perfusion. Because we did not reperfuse these hearts for more than 60 min, the possibility that the additive effects of volatile anesthetics and HOE 642 represent a phenomenon related to early reperfusion only cannot be excluded.
The importance of preservation of energy metabolic status, particularly with respect to high-energy phosphate content, requires comment. In our study, we did not find improved high-energy phosphate preservation except with HOE 642 alone or combined with either isoflurane or sevoflurane when ATP levels were higher and also associated with the most favorable recovery and diminished contracture. These results suggest that high-energy phosphate preservation at the end of reperfusion does not contribute extensively to improved recovery with volatile anesthetics alone; however, preserved ATP stores with the HOE 642 and volatile anesthetic combination may contribute, at least in part, to attenuation of contracture. Other studies have, however, reported that volatile anesthetics preserve ATP stores in stunned canine myocardium [16 ] and in isolated rat hearts subjected to brief (15 min) periods of ischemia. [17 ] The reasons for the apparent differences between those reports and our findings are uncertain but may reflect different experimental designs or durations of ischemia. We must also add that a recent study found that both isoflurane and halothane increased ATP content in preconditioned reperfused ischemic rat hearts in the absence of improved ventricular recovery, thereby suggesting a dissociation between energy metabolic status and contractile recovery. [34 ] Thus the exact role of high-energy phosphate preservation in mediating the salutary effects of volatile anesthetics requires further studies.
Despite the absence of a precise mechanistic basis for the effect, our studies suggest that the use of HOE 642 in combination with the volatile anesthetics isoflurane or sevoflurane exerts not only protective effects but also an additive protective influence resulting in superior recovery of function. Sufentanil, on the other hand, had no protective effects and produced a sustained elevation in left ventricular end-diastolic pressure during reperfusion. Although the mechanism for the latter effect is unknown, it was completely prevented by HOE 642. Furthermore, the salutary actions of HOE 642 in terms of improved functional recovery after reperfusion were unaffected by the opioid.
The authors thank Dr. Wolfgang Scholz of Hoechst-Marion-Roussel, Frankfurt, Germany, for the generous gift of HOE 642 (cariporide); Dr. Adrian W Gelb for his interest in this study and for helpful discussions; and Christopher Webb for technical assistance in doing the gas chromatographic analysis of volatile anesthetics.
References 
References 
Fliegel L, Frohlich O: The Na/H exchanger: An update on structure, regulation and cardiac physiology. Biochem J 1993; 296:273-85.
Lazdunski M, Frelin C, Vigne P: The sodium/hydrogen exchange system in cardiac cells: Its biochemical and pharmacological properties and its role in regulating internal concentrations of sodium and internal pH. J Mol Cell Cardiol 1985; 17:1029-42.
Karmazyn M, Moffat MP: Role of Na/H exchange in cardiac physiology and pathophysiology: Mediation of myocardial reperfusion injury by the pH paradox. Cardiovasc Res 1993; 27:915-24.
Karmazyn M: Role of sodium-hydrogen exchange in mediating myocardial ischemic and reperfusion injury: mechanisms and therapeutic implications, The Na/H Exchange. Edited by L Fliegel. Austin, TX, Landes Bioscience Publishers, 1996.
Karmazyn M: The sodium-hydrogen exchange system in the heart: Its role in ischemic and reperfusion injury and therapeutic implications. Can J Cardiol 1996; 12:1074-82.
Pierce GN, Czubryt MP: The contribution of ionic imbalance to ischemia/reperfusion-induced injury. J Mol Cell Cardiol 1995; 27:53-63.
Karmazyn M: Sodium-hydrogen exchange inhibition: A superior cardioprotective strategy. J Thorac Cardiovasc Surg 1996; 112:776-7.
Freedman BM, Hamm DP, Everson CT, Wechsler AS, Christian CM II: Enflurane enhances postischemic functional recovery in the isolated rat heart. Anesthesiology 1985; 62:29-33.
Warltier DC, Al-Wathiqui MH, Kampine JP, Schmeling WT: Recovery of contractile function of stunned myocardium in chronically instrumented dogs is enhanced by halothane or isoflurane. Anesthesiology 1988; 69:552-65.
Coetzee A, Brits W, Genade S, Lochner A: Halothane does have protective properties in the isolated ischemic rat heart. Anesth Analg 1991; 73:711-9.
Buljubasic N, Marijic J, Stowe DF, Kampine JP, Bosnjak ZJ: Halothane reduces dysrhythmias and improves contractile function after global hypoperfusion in isolated hearts. Anesth Analg 1992; 74:384-94.
Buljubasic N, Stowe DF, Marijic J, Roerig DL, Kampine JP, Bosnjak ZJ: Halothane reduces release of adenosine, inosine, and lactate with ischemia and reperfusion in isolated hearts. Anesth Analg 1993; 76:54-62.
Coetzee A, Moolman J: Halothane and the reperfusion injury in the intact animal model. Anesth Analg 1993; 76:734-44.
Lochner A, Harper IS, Salie R, Genade S, Coetzee AR: Halothane protects the isolated rat myocardium against excessive total intracellular calcium and structural damage during ischemia and reperfusion. Anesth Analg 1994; 79:226-33.
Kanaya N, Fujita S: The effects of isoflurane on regional myocardial contractility and the metabolism in “stunned” myocardium in acutely instrumented dogs. Anesth Analg 1994; 79:447-54.
Kanaya N, Kobayashi I, Nakayama M, Fujita S, Namiki A: ATP sparing effect of isoflurane during ischemia and reperfusion in the canine heart. Br J Anaesth 1995; 74:563-8.
Oguchi T, Kashimoto S, Yamaguchi T, Nakamura T, Kumazawa T: Comparative effects of halothane, enflurane, isoflurane, and sevoflurane on function and metabolism in the ischaemic rat heart. Br J Anaesth 1995; 74:569-75.
Lynch C: Mechanism of myocardial protection by isoflurane: Role of adenosine triphosphate-regulated potassium (K sub ATP) channels. Anesthesiology 1996; 85:27A.
Kersten JR, Lowe D, Hettrick DA, Pagel PS, Gross GJ, Warltier DC: Glyburide, a K-ATP channel antagonist, attenuates the cardioprotective effects of isoflurane in stunned myocardium. Anesth Analg 1996; 83:27-33.
Kersten JR, Schmeling TJ, Hettrick DA, Pagel PS, Gross GJ, Warltier DC: Mechanism of myocardial protection by isoflurane: Role of adenosine triphosphate-regulated potassium (K sub ATP) channels. Anesthesiology 1996; 85:794-807.
Schultz JEL, Hsu AK, Gross GJ: Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. Circ Res 1996; 78:1100-4.
Chen YT, Lin CJ, Lee AY, Chen JS, Hwang DS: Stereospecific blocking effects of naloxone against hemodynamic compromise and ventricular dysfunction due to myocardial ischemia and reperfusion. Int J Cardiol 1995; 50:125-9.
Boban M, Stowe DF, Buljubasic N, Kampine JP, Bosnjak ZJ: Direct comparative effects of isoflurane and desflurane in isolated guinea pig hearts. Anesthesiology 1992; 76:775-80.
Haworth RA, Goknur AB: Inhibition of sodium/calcium exchange and calcium channels of heart cells by volatile anesthetics. Anesthesiology 1995; 82:1255-65.
Bergmeyer HU: Methods in Enzymatic Analysis. New York, Academic Press, 1963.
Scholz W, Albus U, Counillon L, Gogelein H, Lang H-J, Linz W, Weichert A, Scholkens BA: Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc Res 1995; 29:260-8.
Wheeler DM, Katz A, Rice T, Hansford RG: Volatile anesthetic effects on sarcoplasmic reticulum Ca content and sarcolemmal Ca flux in isolated rat cardiac cell suspensions. Anesthesiology 1994; 80:372-82.
Wilde DW, Davidson BA, Smith MD, Knight PR: Effects of isoflurane and enflurane on intracellular Ca sup 2+ mobilization in isolated cardiac myocytes. Anesthesiology 1993; 79:73-82.
Tavernier BM, Adnet PJ, Imbenotte M, Etchrivi TS, Reyford H, Haudecoeur G, Scherpereel P, Horber RM: Halothane and isoflurane decrease calcium sensitivity and maximal force in human skinned cardiac fibers. Anesthesiology 1994; 80:625-33.
Stowe DF, Sprung J, Turner LA, Kampine JP, Bosnjak ZJ: Differential effects of halothane and isoflurane on contractile force and calcium transients in cardiac purkinje fibers. Anesthesiology 1994; 80:1360-8.
Pagel PS, Kampine JP, Schmeling WT, Warltier DC: Reversal of volatile anesthetic-induced depression of myocardial contractility by extracellular calcium also enhances left ventricular diastolic function. Anesthesiology 1993; 78:141-54.
Han J, Kim E, Ho WK, Earm YE: Effects of volatile anesthetic isoflurane on ATP-sensitive K sup + channels in rabbit ventricular myocytes. Biochem Biophys Res Commun 1996; 229:852-6.
Grover GJ: The role of ATP-sensitive potassium channels in myocardial ischemia: Pharmacology and implications for the future, Myocardial Ischemia: Mechanisms, Reperfusion, Protection. Edited by M Karmazyn. Basel, Birkhauser Verlag, 1996, pp 313-24.
Boutros A, Wang J, Capuano C: Isoflurane and halothane increase adenosine triphosphate preservation, but do not provide additive recovery of function after ischemia, in preconditioned rat hearts. Anesthesiology 1997; 86:109-17.
Figure 1. Effects of sevoflurane (SEVO) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for SEVO + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with control at all times during reperfusion and compared with sevoflurane alone for the first 15 min. The sevoflurane-alone group was significantly higher than controls from 15 min until the end of reperfusion.
Figure 1. Effects of sevoflurane (SEVO) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for SEVO + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with control at all times during reperfusion and compared with sevoflurane alone for the first 15 min. The sevoflurane-alone group was significantly higher than controls from 15 min until the end of reperfusion.
Figure 1. Effects of sevoflurane (SEVO) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for SEVO + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with control at all times during reperfusion and compared with sevoflurane alone for the first 15 min. The sevoflurane-alone group was significantly higher than controls from 15 min until the end of reperfusion.
×
Figure 2. Examples of developed pressure recordings from a control heart (A) or a heart to which HOE 642 and sevoflurane were added (B). Ischemia (I) and reperfusion (R) were each initiated for 60 min. The horizontal marker bar indicates 20 min, whereas the vertical bar indicates 20 mmHg developed pressure. Note the reduced increase in end-diastolic pressure with the drug combination and the more rapid and pronounced recovery of developed pressure, which reached a maximum value of 127% of preischemia values.
Figure 2. Examples of developed pressure recordings from a control heart (A) or a heart to which HOE 642 and sevoflurane were added (B). Ischemia (I) and reperfusion (R) were each initiated for 60 min. The horizontal marker bar indicates 20 min, whereas the vertical bar indicates 20 mmHg developed pressure. Note the reduced increase in end-diastolic pressure with the drug combination and the more rapid and pronounced recovery of developed pressure, which reached a maximum value of 127% of preischemia values.
Figure 2. Examples of developed pressure recordings from a control heart (A) or a heart to which HOE 642 and sevoflurane were added (B). Ischemia (I) and reperfusion (R) were each initiated for 60 min. The horizontal marker bar indicates 20 min, whereas the vertical bar indicates 20 mmHg developed pressure. Note the reduced increase in end-diastolic pressure with the drug combination and the more rapid and pronounced recovery of developed pressure, which reached a maximum value of 127% of preischemia values.
×
Figure 3. Effects of isoflurane (ISOF) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for the ISOF + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with controls at all times during reperfusion and compared with isoflurane alone for the first 25 min. The isoflurane-alone group was significantly higher than controls from 25 min until the end of reperfusion.
Figure 3. Effects of isoflurane (ISOF) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for the ISOF + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with controls at all times during reperfusion and compared with isoflurane alone for the first 25 min. The isoflurane-alone group was significantly higher than controls from 25 min until the end of reperfusion.
Figure 3. Effects of isoflurane (ISOF) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for the ISOF + HOE group versus all other treatments. n = 6 for all groups except control (n = 7). Values for HOE alone were significantly higher compared with controls at all times during reperfusion and compared with isoflurane alone for the first 25 min. The isoflurane-alone group was significantly higher than controls from 25 min until the end of reperfusion.
×
Figure 4. Effects of sufentanil (SUFN) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for either the HOE-alone or HOE + SUFN groups compared with the two other treatments. #P < 0.05 from control. n = 6 for all groups except control (n = 7).
Figure 4. Effects of sufentanil (SUFN) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for either the HOE-alone or HOE + SUFN groups compared with the two other treatments. #P < 0.05 from control. n = 6 for all groups except control (n = 7).
Figure 4. Effects of sufentanil (SUFN) or HOE 642 alone or in combination on left ventricular developed pressure and left ventricular end-diastolic pressure during reperfusion after 60 min of ischemia in hearts. Values are mean +/- SEM and depict the percentage of preischemic values. *P < 0.05 for either the HOE-alone or HOE + SUFN groups compared with the two other treatments. #P < 0.05 from control. n = 6 for all groups except control (n = 7).
×
Figure 5. Changes in maximum left ventricular end-diastolic pressure (LVEDP) and the time to peak LVEDP during 60 min of ischemia. Values are mean +/- SEM. C = control; S = sevoflurane (Sevo); I = isoflurane (Isof); SF = sufentanil (Sufn); H = HOE 642. *P < 0.05 compared with unlabeled groups.
Figure 5. Changes in maximum left ventricular end-diastolic pressure (LVEDP) and the time to peak LVEDP during 60 min of ischemia. Values are mean +/- SEM. C = control; S = sevoflurane (Sevo); I = isoflurane (Isof); SF = sufentanil (Sufn); H = HOE 642. *P < 0.05 compared with unlabeled groups.
Figure 5. Changes in maximum left ventricular end-diastolic pressure (LVEDP) and the time to peak LVEDP during 60 min of ischemia. Values are mean +/- SEM. C = control; S = sevoflurane (Sevo); I = isoflurane (Isof); SF = sufentanil (Sufn); H = HOE 642. *P < 0.05 compared with unlabeled groups.
×
Table 1. Baseline Values of LV Developed Pressure 
Image not available
Table 1. Baseline Values of LV Developed Pressure 
×
Table 2. Rates of LV Pressure Development (+dP/dt) and LV Relaxation (-dP/dt) as a Percentage of Baseline during Reperfusion (5, 30, and 60 min) 
Image not available
Table 2. Rates of LV Pressure Development (+dP/dt) and LV Relaxation (-dP/dt) as a Percentage of Baseline during Reperfusion (5, 30, and 60 min) 
×
Table 3. Energy Metabolite Concentrations 
Image not available
Table 3. Energy Metabolite Concentrations 
×